(Q36759527)

16 August 2017

1 reference

title

Medical technologies for the diagnosis of prostate cancer (English)

1 reference

16 August 2017

1 reference

Nicholas J Fitzsimons

series ordinal

1

1 reference

PubMed ID

17359227

16 August 2017

Leon Sun

series ordinal

2

1 reference

PubMed ID

17359227

16 August 2017

Judd W Moul

series ordinal

3

1 reference

16 August 2017

1 March 2007

1 reference

Expert Review of Medical Devices

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

2

1 reference

16 August 2017

227-239

1 reference

Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Viewpoint: expanding prostate cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Prevention of prostate cancer with finasteride: US/European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Relationship of demographic and clinical factors to free and total prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Proteomic patterns: their potential for disease diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

uPM3, a new molecular urine test for the detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Clinical potential of proteomics in the diagnosis of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Serum proteomic patterns for detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Autoantibody signatures in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Random systematic sextant biopsy versus power doppler ultrasound-guided target biopsy in the diagnosis of prostate cancer: positive rate and clinicopathological features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Contrast specific imaging in the detection and localization of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Anatomy and pathology of the male pelvis by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Visualization of prostate cancer with 11C-choline positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Prospective study comparing two methods of anaesthesia for prostate biopsies: apex periprostatic nerve block versus intrarectal lidocaine gel: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

The rectal administration of lidocaine gel and tolerance of transrectal ultrasonography-guided biopsy of the prostate: a prospective randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Comparison of local anesthesia techniques during transrectal ultrasound-guided biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Comparison of 3 different methods of anesthesia before transrectal prostate biopsy: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Lidocaine suppositories for prostate biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Diclofenac suppository analgesia for transrectal ultrasound guided biopsies of the prostate: a double-blind, randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Comparison of different local anesthesia techniques during TRUS-guided biopsies: a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

How to decrease pain during transrectal ultrasound guided prostate biopsy: a look at the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Entonox analgesia for prostatic biopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Can we obtain better specimens with an end-cutting prostatic biopsy device?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Construction of tissue microarrays from prostate needle biopsy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

RETRACTED: Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Gene therapy for cancer treatment: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

Computer technology in detection and staging of prostate carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17434440.4.2.227

21 January 2018

Identifiers

DOI

10.1586/17434440.4.2.227

1 reference

16 August 2017

1 reference

PubMed ID

17359227